NANJING, SHANGHAI, CHINA, SAN JOSE & SAN FRANCISCO, CALIF., U.S., March 1, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing...
NANJING&SHANGHAI , CHINA, SAN JOSE U.S., February 14, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing i...
SEATTLEandSAN FRANCISCOandSAN JOSE, Calif.andNANJING,Chinaand SUZHOU, ChinaandSHANGHAI,Jan. 11, 2022/PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and deliverin...
SAN JOSE & SAN FRANCISCO, CALIF., U.S., NANJING & SHANGHAI CHINA, Dec. 13, 2021 – IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company focused on discovering, ...
SAN JOSE, CALIF., NANJING, and SHANGHAI, Oct 26, 2021 - – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innov...
SAN JOSE, CALIF., NANJING, CHINA and SHANGHAI, Nov 10, 2021 – IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturin...
SAN JOSE, Calif.., NANJING, China and SHANGHAI, November 9, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturi...
Brings strong track record with over two decades in capital markets, financial management and scientific researchPLEASANTON, CALIF. & NANJING, SHANGHAI, CHINA, October 19, 2021 – IASO Biothe...
IASO Biotherapeutics bagged a hefty $108 million to fuel a teeming pipeline of cell therapies and antibodies for cancer and autoimmune disease. The series C round brings the company’s total rais...
September 16, 2021, PLEASANTON, Calif. & NANJING, SHANGHAI, China – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manuf...